I-Deoxyarbutin, njenge-Tyrosinase inhibitor encintisanayo, ingalawula ukukhiqizwa kwe-melanin, inqobe umbala, iphele amabala amnyama esikhumbeni, futhi ibe nomthelela osheshayo futhi ohlala njalo wokuba mhlophe kwesikhumba. Umthelela ovimbelayo we-deoxyaarbutin ku-Tyrosinase ngokusobala uphakeme kunezinye izivuseleli ezimhlophe, futhi umphumela wokuba mhlophe nokukhanya ungafinyelelwa ngenani elincane lokusetshenziswa. I-Deoxyarbutin nayo inemiphumela enamandla ye-antioxidant
- Igama lesiShayina elithi Deoxyarbutin
- Igama langaphandle Deoxyarbutin
- Isiteketiso p - (tetrahydro-2H-pyran-2-oxy) phenol
- Ifomula yekhemikhali C11H14O3
- Isisindo se-molecule 194.23
- Inombolo yokungena ye-CAS 53936-56-4
- Isibizo sesiNgisi esithi 4- [(Tetrahydro-2H-pyran-2-yl) oxy] phenol
- Ukuhlanzeka ≥ 98%
I-Deoxyarbutinnjengesizukulwane esisha se-cosmetic brightening and whitening ejenti esebenzayo, isetshenziswa kakhulu kuzimonyo ezithuthukisiwe ezimhlophe.
Hlola
Ukushintshashintsha kwe-melanogenesis kuma-melanocyte kungafinyelelwa kusetshenziswa amakhemikhali abelana nge-homologies yesakhiwo ne-substrate tyrosine futhi ngaleyo ndlela avimbele ngokuncintisana umsebenzi we-catalytic we-tyrosinase. Senze i-tyrosinase inhibitor entsha, i-deoxyArbutin (dA), ngokusekelwe kulesi sisekelo. I-DeoxyArbutin ibonisa ukuvinjelwa okusebenzayo kwekhowe tyrosinase in vitro nge-Ki ephansi ngokuphindwe ka-10 kune-hydroquinone (HQ) futhi ingaphansi ngokuphindwe ngama-350 kune-arbutin. Kumodeli ye-Guinea pig engenaboya, enemibala, i-dA ibonise ukukhanya kwesikhumba okusheshayo nokuqhubekayo okwakwazi ukuhlehliswa ngokuphelele phakathi kwamaviki angu-8 ngemva kokumiswa kokusetshenziswa kwesihloko.
Ngokuphambene, i-HQ idale umphumela wokukhanyisa isikhumba omfushane kodwa ongasimeme kanti i-kojic acid ne-arbutin azibonisi umphumela wokukhanya kwesikhumba. Imiphumela evela kuphaneli yokuhlolwa kokuphepha isekele ukusungulwa sekukonke kwe-dA njenge-molecule esebenzayo. Ocwaningweni lomtholampilo lwabantu, ukwelashwa kwe-dA ngamaviki angu-12 kuphumele ekuncipheni okuphawulekayo noma okuncane ekukhanyeni kwesikhumba kukonke kanye nokwenza ngcono kwamalentijine elanga esixukwini sesikhumba esikhanyayo noma abantu besikhumba esimnyama, ngokulandelana. Le datha ibonisa ukuthi i-dA inomsebenzi ongaba khona we-tyrosinase inhibitory ongaholela ekukhanyeni kwesikhumba futhi ingase isetshenziselwe ukuthambisa izilonda ze-hyperpigmentary.
Isingeniso
I-Melasma (i-chloasma) isifo esivamile se-pigmentary yesikhumba esibonakala ngokukhanya okungavamile kuya kumabala ansundu ebusweni, okuvamise ukubangela imithwalo emikhulu yengqondo nengokwengqondo kubantu abathintekile. Nokho, izenzakalo ezikhuthazayo ze-pathogenesis ye-melasma aziqondwa kahle. I-Melasma ivame kakhulu kubantu abanezinhlobo zesikhumba ze-Fitzpatrick IV kuya ku-VI kunalabo abanesikhumba esimhlophe (izinhlobo I kuya ku-III). I-Melasma yaziwa nangokuthi ivame kakhulu phakathi kwabesifazane kunabesilisa futhi ivame kakhulu kubantu base-Asia, Latinos kanye nabase-Afrika-baseMelika kunaphakathi kwamaCaucasus. Balinganiselwa ku-50% kuya ku-70% abesifazane abakhulelwe e-US bahlakulela i-melasma [3].
Kuye kwatholakala ukuthi ama-melanocyte angasebenzi kahle esikhumbeni se-melasma akhiqiza i-melanin pigment eyengeziwe nge-tyrosine catabolism pathway. I-Tyrosinase (EC 1.14.18.1), i-glycoprotein equkethe ithusi, iyi-enzyme ekhawulela isilinganiso ebalulekile kule ndlela. Ukwenziwa kwe-melanin kwenzeka phakathi kwama-organelle akhethekile abizwa ngokuthi ama-melanosomes bese kuthi ama-melanosome adluliselwe esuswa kuma-melanocyte aye kuma-keratinocyte angomakhelwane, ngaleyo ndlela kunqunywe umbala wesikhumba osungulayo futhi osebenzayo. Ama-ejenti amaningi akhanyisa isikhumba aqondiswe ekulawuleni ukuhlanganiswa kwe-melanin ngokucindezelwa komsebenzi we-tyrosinase. Eminyakeni engu-50 edlule, i-hydroquinone (1, 4-benzenediol, HQ) ibisetshenziswa kabanzi njengezinga legolide le-prototypical tyrosinase inhibitors ekwelapheni i-melasma. Kodwa-ke, ukunaka okukhulu kwamuva nje kukhokhwe engcupheni yezempilo engaba khona yokuchayeka isikhathi eside ku-HQ, njenge-exogenous ochronosis, i-leukoderma (occupational vitiligo), ngisho ne-carcinogenesis .Kuyamukelwa ngokuvamile ukuthi i-HQ cishe isebenza njenge-substrate yokuncintisana ngokuncintisana umsebenzi, enikeza amandla okuba mhlophe kwesikhumba. Phakathi naleso sikhathi, lezi zinhlanganisela ze-monophenol nazo zibangela, ngokusebenzisa i-enzymatic oxidation nge-tyrosinase, kuma-radicals amaningi mahhala abangela i-lipid peroxidation kanye nomphumela wokulimala kolwelwesi lwe-melanosomal .Ocwaningweni lwangaphambilini oluvela elabhorethri yethu kuye kwaboniswa ukuthi i-deoxyarbutin (4--[(tetrahydro-2H) -pyran-2-yl) oxy] phenol, D-Arb), iglucoside okuphuma ku-HQ, iphephe kakhudlwana futhi ine-cytotoxic encane uma iqhathaniswa ne-hydroquinone eyinhlanganisela kamama . Ucwaningo lwamanje lwenziwe ukuze kuphenywe ubuthi nokusebenza kwe-D-Arb ezingeni le-sub-cellular (ngokuqondile kuma-melanosomes) kanye nombala wesikhumba kusetshenziswa amamodeli e-vivo kanye ne-in vitro, kuqhutshekwe nokuhlola i-biosafety ye-D-Arb ngokuqhathanisa ne-HQ. ukusetshenziswa kokukhanyisa isikhumba.
I-Deoxyarbutin, njengesizukulwane esisha se-cosmetic brightening and whitening ejenti esebenzayo, isetshenziswa kakhulu kuzimonyo ezithuthukisiwe ezimhlophe.
I-D-Arbutin ingenye yezinto eziphuma ku-Arbutin, ebizwa ngokuthi i-D-nenenebb arbutin, engavimbela ngempumelelo isenzo se-tyrosinase ezicutshini zesikhumba. Ngokocwaningo, umphumela wawo uphindwe ka-10 kune-hydroquinone futhi izikhathi ezingama-350 kune-Arbutin ejwayelekile. Ekuhlolweni kwesikhumba sesilwane, le D-Arbutin ingenza isikhumba sibe mhlophe ngokushesha nangempumelelo, futhi ngemva kokuyeka ukusebenzisa, umphumela usengagcinwa cishe amasonto ayi-8.
Ezifundweni zemitholampilo emzimbeni womuntu, ukusetshenziswa kwesihloko kwe-D-Arbutin amasonto ayi-12 kungazuza imiphumela ebalulekile yokukhanya kwesikhumba, futhi kunomphumela omuhle wokuthuthuka ezindaweni zokuchayeka ekukhanyeni kwansuku zonke nezimo zesikhumba esimnyama.
Isikhathi sokuthumela: Jul-11-2023
